J. Ylä-Pelto, L. Tripathi, P. Susi: Therapeutic Use of Native and Recombinant Enteroviruses. In: Viruses. Band 8, Nummer 3, Februar 2016, S. 57, doi:10.3390/v8030057, PMID 26907330, PMC 4810247 (freier Volltext).
C. Goetz et al.: Oncolytic poliovirus against malignant glioma. Future Virology, Vol. 6, Nr. 9 (2011), S. 1045–1058. doi:10.2217/fvl.11.76, PMC 3187927 (freier Volltext)
Eda K. Holl et al.: Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget, Nr. 7 (2016); S. 79828–79841. doi:10.18632/oncotarget.12975, PMC 5346754 (freier Volltext)
J. Ylä-Pelto, L. Tripathi, P. Susi: Therapeutic Use of Native and Recombinant Enteroviruses. In: Viruses. Band 8, Nummer 3, Februar 2016, S. 57, doi:10.3390/v8030057, PMID 26907330, PMC 4810247 (freier Volltext).
C. Goetz et al.: Oncolytic poliovirus against malignant glioma. Future Virology, Vol. 6, Nr. 9 (2011), S. 1045–1058. doi:10.2217/fvl.11.76, PMC 3187927 (freier Volltext)
Eda K. Holl et al.: Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget, Nr. 7 (2016); S. 79828–79841. doi:10.18632/oncotarget.12975, PMC 5346754 (freier Volltext)
rp-online.de
PVS-RIPO heilt Krebs laut rponline vom 2. April 2015, abgerufen am 11. Dezember 2016